T-CiRA Discovery, Research, Takeda Pharmaceutical Company Limited, 26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa, 251-8555, Japan.
Takeda-CiRA Joint Program for iPS Cell Applications (T-CiRA), Fujisawa, Kanagawa, Japan.
Sci Rep. 2022 Mar 18;12(1):4740. doi: 10.1038/s41598-022-08753-5.
The differentiation of pancreatic endocrine cells from human pluripotent stem cells has been thoroughly investigated for their application in cell therapy against diabetes. Although non-endocrine cells are inevitable contaminating by-products of the differentiation process, a comprehensive profile of such cells is lacking. Therefore, we characterized non-endocrine cells in iPSC-derived pancreatic islet cells (iPIC) using single-cell transcriptomic analysis. We found that non-endocrine cells consist of (1) heterogeneous proliferating cells, and (2) cells with not only pancreatic traits but also liver or intestinal traits marked by FGB or AGR2. Non-endocrine cells specifically expressed FGFR2, PLK1, and LDHB. We demonstrated that inhibition of pathways involving these genes selectively reduced the number of non-endocrine cells in the differentiation process. These findings provide useful insights into cell purification approaches and contribute to the improvement of the mass production of endocrine cells for stem cell-derived cell therapy for diabetes.
从人多能干细胞中分化产生的胰腺内分泌细胞,因其在糖尿病细胞治疗中的应用而受到深入研究。尽管非内分泌细胞是分化过程中不可避免的混杂副产物,但对于这些细胞的全面特征还缺乏了解。因此,我们使用单细胞转录组分析对 iPSC 来源的胰岛细胞(iPIC)中的非内分泌细胞进行了特征描述。我们发现,非内分泌细胞包括(1)异质性增殖细胞,和(2)不仅具有胰腺特征,而且还具有肝脏或肠道特征的细胞,这些特征由 FGB 或 AGR2 标记。非内分泌细胞特异性表达 FGFR2、PLK1 和 LDHB。我们证明,涉及这些基因的通路的抑制可以选择性地减少分化过程中非内分泌细胞的数量。这些发现为细胞纯化方法提供了有用的见解,并有助于改善用于糖尿病的干细胞衍生细胞治疗的内分泌细胞的大量生产。